Clinical TrialJul 2, 2026, 08:32 AM
Trinity Biotech Unveils CGM+ Clinical Data on False Lows
AI Summary
Trinity Biotech plc announced positive clinical trial data for its CGM+ solution. The analysis of over 5,000 hours of wear data validated CGM+'s ability to distinguish nocturnal compression-related false low glucose events from true blood glucose lows. This capability addresses a common limitation of conventional continuous glucose monitoring systems, improving user experience and strengthening the commercial opportunity for CGM+ within the global CGM market. The company plans to incorporate this function into CGM+ as it moves towards pivotal trials and regulatory submission.
Key Highlights
- Analysis of over 5,000 hours of clinical wear data validated CGM+ capability.
- CGM+ distinguishes nocturnal compression-related false lows from true blood glucose lows.
- Demonstrates practical value of Trinity Biotech's proprietary multi-sensor biosensor technology.
- Reinforces differentiation opportunity for CGM+ within the $15 billion global CGM market.
- Algorithm developed to identify false low glucose readings caused by sensor compression.
- CGM+ is in latter stages of development, with this function for pivotal trial and regulatory submission.
Price Impact
More from TRIB